查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867226

按产品类型、给药途径和分销管道分類的消化器官系统药物市场－2025-2032年全球预测

Gastrointestinal Agents Market by Product Type, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，消化器官系统药物市场将成长至 896.4 亿美元，复合年增长率为 5.13%。

关键市场统计数据
基准年 2024 600.6亿美元
预计年份：2025年 631.2亿美元
预测年份 2032 896.4亿美元
复合年增长率 (%) 5.13%

简要概述了目前影响消化器官系统药物研发和分销的临床驱动因素、商业性趋势和策略重点。

在临床实践不断变化、患者期望日益提高以及科学快速发展的多重压力下，消化器官系统药物市场模式持续演变。本执行摘要概述了影响胃肠道治疗领域产品开发、商业化和供应链管理决策的治疗类别、临床因素和商业性趋势。

科学进步、数位化医疗模式、监管以及基于价值的支付趋势正在共同重塑治疗重点、商业模式和供应链策略。

在科学发展、病人期望和不断演变的医疗服务模式的推动下，消化器官系统病学领域正经历着变革性的转变。我们对肠道微生物群和宿主-微生物相互作用的理解不断加深，使得益生菌、益生元和靶向微生物群疗法从辅助性治疗跃升为治疗研发的核心组成部分；与此同时，精准医疗方法正将生物标誌物指导的治疗选择纳入到以往主要关注症状管理的讨论中。

评估美国关税政策调整对消化器官系统治疗供应链的采购决策、製造韧性和跨职能协作的影响

影响医药原料和成品的2025年关税环境已成为产业相关人员面临的重要策略转捩点。活性药物成分、辅料、包装材料和成品剂型的关税调整正在影响采购决策、利润管理和采购布局。各公司正透过重新评估供应商组合、加快二级资讯来源资格认证以及建立缓衝库存来应对这一变化，从而降低采购波动的影响。

深入的市场细分洞察揭示了产品类型、给药途径和分销管道的差异如何决定临床定位、製剂策略和商业性执行。

市场区隔驱动目标策略的製定，并明确了临床差异化与商业性机会的交会点。根据产品类型，市场涵盖急性症状类药物，例如制酸剂和止吐药；动力和分泌治疗层级，例如H2受体拮抗剂和质子帮浦阻断剂；以及支持性治疗类药物，包括泻药和益生元/益生菌（基于微生物组科学的方法）。在制酸剂中，氢氧化铝、碳酸钙、氢氧化镁、碳酸氢钠及其组合药物的差异会影响製剂策略、患者耐受性以及非处方药的定位。止泻药分为吸附剂和鸦片类衍生物，其中吸附剂包括次水杨酸铋和高岭土果胶，鸦片类衍生物包括地芬诺酯、阿托品和洛哌丁胺。每种药物都有其独特的安全性和监管特性。止吐药依作用机转可分为多巴胺拮抗剂、NK1受体拮抗剂及5-羟色胺受体拮抗剂。在这些类别中，一些特定分子，例如甲氧氯普胺、丙氯Aprepitant、阿瑞吡坦、Palonosetron，OndansetronGranisetron定位和药物目录的讨论。 H2受体拮抗剂包括西咪替丁、法莫替丁、尼札替丁和雷尼替丁等药物。质子帮浦阻断剂包括Esomeprazole、兰索拉唑、奥美拉唑、泮托拉唑和Rabeprazole。每个亚类都有不同的生命週期管理和病患依从性的考量。泻药分为容积性泻药、润滑性泻药、渗透性泻药、刺激性泻药、软便剂。填充剂包括甲基纤维素、聚卡波非和车前子，而渗透剂包括乳果糖、聚乙二醇和山梨醇。这些差异对于临床指引、医病沟通以及非处方药和处方药的市场动态至关重要。益生菌和益生元包括益生元（如寡果醣和菊糖）以及益生菌菌株（如双歧桿菌、乳酸桿菌和布拉氏酵母菌），这些菌株具有特定的证据要求和监管途径。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大微生物组调节疗法在功能性胃肠疾病治疗的应用
  • 肽类疗法在进行性发炎性肠道疾病治疗的应用日益广泛
  • 将数位健康解决方案和远端监测相结合用于慢性胃肠道疾病的治疗
  • 用于早期检测胃肠道癌症的非侵入性诊断生物标记的需求日益增长
  • 研发管线日益着重于针对乳糜泻和麸质敏感性的标靶治疗。
  • 开发具有更高安全性的新一代质子帮浦阻断剂
  • 针对肠大肠激躁症（IBS）和功能性疾病的肠脑轴调节临床研究正在迅速增加。
  • 溃疡性大肠炎和克隆氏症口服小分子疗法的创新
  • 在胃肠道发炎性疾病领域，生物相似药正与原厂生物製药竞争。
  • 在胃肠医学中引入基于基因组分析的个人化医疗方法

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章消化器官系统药物市场（依产品类型划分）

  • 制酸剂
    • 氢氧化铝
    • 碳酸钙
    • 组合药物
    • 氢氧化镁
    • 碳酸氢钠
  • 止泻
    • 吸附剂
      • 次水杨酸铋
      • 高岭土果胶
    • 鸦片类衍生物
      • 阿托品二苯氧酯
      • 洛哌丁胺
  • 止吐药
    • 多巴胺拮抗剂
      • 甲氧氯普胺
      • 丙氯拉嗪
    • NK1受体拮抗剂
      • Aprepitant
      • 福沙普利坦
    • 血清素受体拮抗剂
      • Granisetron
      • Ondansetron
      • Palonosetron
  • H2受体拮抗剂
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 泻药
    • 粪便膨胀剂
      • 甲基纤维素
      • 聚卡波非
      • 车前子
    • 润滑剂
    • 渗透压
      • 乳果糖
      • 聚乙二醇
      • 山梨醇
    • 刺激性泻药
    • 软便剂
  • 益生菌和益生元
    • 益生元
      • 寡果醣
      • 菊糖
    • 益生菌
      • 双歧桿菌
      • 乳酸菌
      • 布鲁氏酵母
  • 质子帮浦阻断剂
    • Esomeprazole
    • 兰索拉唑
    • 奥美拉唑
    • 泮托拉唑
    • Rabeprazole

第九章 依给药途径分類的消化器官系统药物市场

  • 肌肉内注射
  • 静脉注射
    • Bolus注
    • 静脉注射
  • 口服
    • 胶囊
    • 液态糖浆
    • 粉末
    • 药片
  • 外用药物
    • 奶油
    • 凝胶
    • 栓剂

第十章消化器官系统药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 各地区消化器官系统药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章消化器官系统药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国消化器官系统药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • AstraZeneca PLC
    • Johnson & Johnson
    • Otsuka Pharmaceutical Co., Ltd.
    • Novartis AG
    • GlaxoSmithKline plc
    • Sanofi SA
    • Bayer AG
Product Code: MRR-CB04E056533F

The Gastrointestinal Agents Market is projected to grow by USD 89.64 billion at a CAGR of 5.13% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 60.06 billion
Estimated Year [2025] USD 63.12 billion
Forecast Year [2032] USD 89.64 billion
CAGR (%) 5.13%

A concise orienting narrative introducing the current clinical drivers commercial dynamics and strategic priorities shaping gastrointestinal agent development and distribution

The pharmaceutical landscape for gastrointestinal agents is evolving under the combined pressures of changing clinical practice, heightened patient expectations, and rapid scientific progress. This executive summary provides an integrated view of the therapeutic classes, clinical drivers, and commercial dynamics that influence decision making for product development, commercialization, and supply chain management within the GI therapeutic area.

Leading therapeutic categories span acute symptom relief through to long-term management of chronic conditions, and each category has distinct clinical profiles, patient adherence patterns, and regulatory considerations. Stakeholders face the dual challenge of optimizing value for payers and patients while sustaining robust pipelines through targeted innovation. By synthesizing clinical trends, distribution shifts, and regulatory signals, this introduction sets the scene for deeper analysis that follows and prepares readers to interpret strategic recommendations in context.

How scientific advances digital care models regulatory scrutiny and value based payment trends are jointly reshaping therapeutic priorities commercial models and supply chain strategies

The gastrointestinal agents sector is experiencing transformative shifts driven by science, patient expectations, and the evolving healthcare delivery model. Advances in our understanding of the gut microbiome and host-microbe interactions have elevated probiotics, prebiotics, and targeted microbiome therapeutics from niche adjuncts to central elements of therapeutic exploration. Meanwhile, precision medicine approaches are bringing biomarker-guided treatment selection into conversations that previously focused primarily on symptom control.

Concurrently, digital health tools and remote care pathways have reshaped how patients access therapy, adhere to regimens, and report outcomes, prompting manufacturers to integrate digital companion offerings and real-world evidence generation into launch plans. Regulatory attention on long-term safety profiles-particularly for widely used drug classes-has prompted manufacturers to invest in lifecycle management, comparative effectiveness studies, and clinician education initiatives. Supply chain resilience has emerged as a strategic priority, with companies diversifying active pharmaceutical ingredient sourcing and adopting manufacturing redundancy to mitigate disruptions.

Finally, payer emphasis on value and outcomes is accelerating adoption of value-based contracting and indication-specific pricing considerations. Collectively, these shifts converge to favor companies that combine therapeutic innovation with pragmatic commercial models, evidence generation, and agile operations, enabling them to respond to clinician preferences and evolving reimbursement pathways.

Assessing how adjustments in US tariff policy have reshaped sourcing decisions manufacturing resilience and cross functional collaboration across gastrointestinal therapeutic supply chains

The 2025 tariff environment affecting pharmaceutical inputs and finished products has introduced a notable strategic inflection point for industry participants. Tariff adjustments that touch active pharmaceutical ingredients, excipients, packaging components, and finished formulations have influenced procurement decisions, margin management, and sourcing footprints. Companies have responded by reassessing supplier portfolios, accelerating qualification of secondary sources, and increasing buffer inventories to smooth procurement volatility.

Operationally, manufacturers have expanded localization strategies where possible and have diversified contract manufacturing partners to reduce single-point dependencies. These approaches have implications for lead times, quality assurance, and regulatory filings, as establishing new manufacturing relationships often requires additional validation and regulatory engagement. In parallel, procurement teams have renegotiated commercial terms and explored hedging strategies to mitigate input cost swings, while commercial teams have engaged payers and distributors to discuss contract adjustments and shared risk models.

From a clinical supply perspective, the tariff context has elevated the importance of robust demand forecasting and integrated supply-chain planning, particularly for critical hospital-administered therapies and intravenous formulations. Regulatory affairs and quality teams have become more actively involved in sourcing decisions to ensure compliance with product registrations and to manage any changes in manufacturing sites or component provenance. Overall, the tariff landscape has reinforced the need for cross-functional collaboration across sourcing, regulatory, manufacturing, and commercial teams to preserve continuity of care and to protect therapeutic access.

Deep segmentation insight revealing how product type administration route and distribution channel distinctions determine clinical positioning formulation strategy and commercial execution

Segmentation drives targeted strategy and clarifies where clinical differentiation and commercial opportunity intersect. Based on product type, the market spans acute symptom categories such as antacids and anti-emetics, therapeutic classes addressing motility and secretion such as H2 receptor antagonists and proton pump inhibitors, and supportive categories including laxatives alongside prebiotic and probiotic approaches that leverage microbiome science. Within antacids, distinctions between aluminum hydroxide, calcium carbonate, magnesium hydroxide, sodium bicarbonate and combination formulations influence formulation strategy, patient tolerability considerations, and over-the-counter positioning. Anti-diarrheals differentiate into adsorbents and opioid derivatives, with adsorbents encompassing bismuth subsalicylate and kaolin pectin and opioid derivatives represented by agents such as diphenoxylate-atropine and loperamide, each presenting unique safety and regulatory profiles. Anti-emetics are further segmented by mechanism into dopamine antagonists, NK1 receptor antagonists and serotonin receptor antagonists, and within these groups specific molecules like metoclopramide, prochlorperazine, aprepitant, fosaprepitant, granisetron, ondansetron and palonosetron shape clinical positioning and formulary conversations. H2 receptor antagonists include agents such as cimetidine, famotidine, nizatidine and ranitidine, and proton pump inhibitors span esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole, with each subclass presenting distinct lifecycle management and patient adherence considerations. Laxatives subdivide into bulk forming, lubricant, osmotic, stimulant and stool softeners, with bulk forming options such as methylcellulose, polycarbophil and psyllium and osmotic options including lactulose, polyethylene glycol and sorbitol; these distinctions matter for clinical guidance, patient counseling and OTC versus prescription dynamics. Probiotics and prebiotics encompass prebiotics like fructooligosaccharides and inulin alongside probiotic strains including bifidobacterium, lactobacillus and saccharomyces boulardii, which introduce strain-specific evidence requirements and regulatory pathways.

Based on route of administration, differentiation across intramuscular, intravenous, oral and topical routes impacts clinical adoption, formulary placement, and manufacturing complexity. Intravenous therapies require attention to bolus injection and infusion formats, while oral dosage forms such as capsules, liquid syrups, powders and tablets demand varied stability and palatability considerations, and topical options including creams, gels and suppositories have unique patient acceptability and dispensing implications. Distribution channels further shape commercialization approaches, with hospital pharmacy dynamics differing from retail pharmacy and online pharmacy ecosystems in terms of procurement cycles, reimbursement mechanisms and stakeholder engagement. Taken together, segmentation clarifies where clinical evidence, formulation investment and commercial strategy should align to capture therapeutic demand and to manage lifecycle priorities effectively.

Regional strategic imperatives across the Americas Europe Middle East & Africa and Asia Pacific that influence access commercialization and manufacturing priorities

Regional dynamics continue to shape how companies prioritize launches, supply resilience, and commercial investments. In the Americas, payers and providers emphasize outcomes, cost containment and real-world evidence, prompting manufacturers to strengthen post-launch evidence generation and to engage in value demonstration activities. North American hospital procurement processes and specialty pharmacy channels influence adoption patterns for hospital-administered and specialty GI therapies, while Latin American dynamics require adaptive pricing strategies and regional manufacturing partnerships to address access constraints.

Europe, Middle East & Africa present a mosaic of regulatory environments and payer structures that necessitate differentiated market entry playbooks. In several European markets, rigorous health technology assessment processes favor therapies with demonstrable comparative effectiveness and cost-utility evidence, while Middle Eastern markets often prioritize rapid access pathways paired with local registration requirements. African markets pose infrastructure and distribution challenges but also opportunities for strategic partnerships that expand access to essential symptomatic therapies and probiotics.

Asia-Pacific demonstrates a heterogeneous mix of mature markets with advanced regulatory frameworks and emerging markets with significant growth in healthcare access. Regional manufacturing capacity in Asia supports a large portion of global API and formulation output, which in turn affects sourcing strategies for global manufacturers. Patient preferences, regulatory timelines, and distribution models in Asia-Pacific require nuanced engagement strategies, including local clinical collaborations and culturally tailored patient support programs to optimize uptake and adherence.

Corporate strategies and tactical maneuvers adopted by manufacturers to strengthen pipelines maximize product lifecycles and optimize distribution in gastrointestinal therapeutics

Companies across the gastrointestinal therapeutic area are pursuing multiple strategic pathways to sustain growth, protect margins, and deliver differentiated clinical value. Firms with established portfolios are investing in lifecycle management strategies such as new formulations, fixed-dose combinations, and indication expansions to maintain relevance in competitive therapeutic classes. Others are pursuing targeted R&D investments in microbiome-based approaches, novel receptor targets, and therapeutic platforms that address unmet needs in chronic GI disorders.

Strategic alliances and selective in-licensing deals have become prevalent as companies seek to accelerate pipeline diversification without bearing full discovery risk. Contract manufacturing and strategic sourcing partnerships provide scalability while enabling firms to focus internal resources on core competencies such as clinical development and market access. Commercially, manufacturers are refining distribution strategies to balance hospital, retail and online pharmacy channels, deploying channel-specific support programs and digital engagement tools to improve patient adherence and clinician awareness.

Furthermore, companies are enhancing their evidence ecosystems by integrating real-world data collection, patient-reported outcome measures, and pragmatic trial designs into development plans to support payer conversations and to inform guideline updates. Operational excellence initiatives that strengthen quality systems, regulatory readiness and supply-chain visibility remain core to sustaining trust among providers and payers, particularly when therapeutic switching or supply reallocation becomes necessary.

Actionable cross functional initiatives recommended for manufacturers to integrate evidence commercialization and supply resilience to advance patient access and competitive differentiation

Industry leaders should prioritize a coordinated agenda that aligns clinical evidence generation with pragmatic commercial execution and resilient operations. First, integrate mechanistic and real-world evidence programs early in development plans to support differentiated claims and to facilitate payer dialogues; investing in biomarker-driven trials and longitudinal patient-reported outcomes will strengthen value propositions. Second, diversify sourcing strategies for APIs and excipients and qualify alternate manufacturing partners to reduce exposure to regional trade disruptions; include regulatory teams early to streamline any required filings associated with manufacturing changes.

Third, tailor distribution strategies to account for channel-specific behaviors: design hospital engagement plans that emphasize formulary and procurement alignment, craft retail pharmacy initiatives to support OTC and chronic care adherence, and develop digital-first approaches for online pharmacy partnerships that enhance patient convenience and retention. Fourth, adopt modular commercial models that incorporate patient support programs, digital adherence tools, and outcome-based contracting pilots where appropriate to align incentives with payers and providers. Finally, foster cross-functional governance that brings R&D, regulatory, manufacturing, and commercial leadership together under a common roadmap to accelerate decision making and to ensure operational readiness for launches and supply shifts.

Methodological approach explaining how qualitative interviews regulatory review and thematic synthesis produced action oriented insights while avoiding speculative market projections

The research underpinning this summary synthesizes primary and secondary methodologies to build a comprehensive and balanced perspective. Qualitative interviews with clinicians, formulary decision makers, procurement leads and industry executives provided directional insight into adoption drivers, supply considerations and payer dynamics. These interviews were triangulated with regulatory guidance, clinical literature, and technical product information to ensure clinical and operational accuracy.

Analytical processes emphasized thematic synthesis rather than quantitative extrapolation, focusing on decision-relevant findings such as formulation tolerability, route-specific adoption patterns, distribution channel nuances, and strategic sourcing implications. Cross-validation steps included internal expert review and scenario analysis to stress-test assumptions about supply vulnerabilities and commercialization approaches. The methodology deliberately prioritized actionable insight generation and practical recommendations while avoiding speculative market sizing, ensuring that conclusions remain evidence-based and relevant for commercial and clinical stakeholders.

Concise concluding perspective that synthesizes clinical evidence commercial strategy and operational readiness as determinants of successful gastrointestinal product execution

In summary, the gastrointestinal agents landscape is at an inflection point where scientific innovation, distribution evolution and supply resilience converge to redefine strategic imperatives. Companies that align therapeutic differentiation with robust evidence generation, agile sourcing strategies, and channel-specific commercial models will be best positioned to navigate regulatory scrutiny and payer expectations. Cross-functional collaboration and early integration of real-world evidence into development plans will accelerate adoption and support value conversations with health systems and payers.

Operational readiness, particularly in manufacturing and procurement, remains essential to mitigate risks introduced by shifting trade policies and to protect continuity of care. Ultimately, pragmatic execution that translates clinical promise into accessible, affordable therapies will determine success across therapeutic classes and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of microbiome modulation therapies to treat functional gastrointestinal disorders
  • 5.2. Rising adoption of peptide-based therapeutics for advanced inflammatory bowel disease management
  • 5.3. Integration of digital health solutions and remote monitoring in chronic gastrointestinal disease treatment
  • 5.4. Growing demand for noninvasive diagnostic biomarkers in early detection of gastrointestinal cancers
  • 5.5. Increasing pipeline focus on targeted therapies for celiac disease and gluten sensitivity
  • 5.6. Development of next generation proton pump inhibitors with improved safety profiles
  • 5.7. Surge in clinical research on gut-brain axis modulation for IBS and functional disorders
  • 5.8. Innovations in oral small molecule therapeutics for ulcerative colitis and Crohn's disease
  • 5.9. Emergence of biosimilar agents competing with originator biologics in GI inflammatory disease
  • 5.10. Adoption of personalized medicine approaches driven by genomic profiling in gastrointestinal care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastrointestinal Agents Market, by Product Type

  • 8.1. Antacids
    • 8.1.1. Aluminum Hydroxide
    • 8.1.2. Calcium Carbonate
    • 8.1.3. Combination Formulations
    • 8.1.4. Magnesium Hydroxide
    • 8.1.5. Sodium Bicarbonate
  • 8.2. Anti Diarrheals
    • 8.2.1. Adsorbents
      • 8.2.1.1. Bismuth Subsalicylate
      • 8.2.1.2. Kaolin Pectin
    • 8.2.2. Opioid Derivatives
      • 8.2.2.1. Diphenoxylate Atropine
      • 8.2.2.2. Loperamide
  • 8.3. Anti Emetics
    • 8.3.1. Dopamine Antagonists
      • 8.3.1.1. Metoclopramide
      • 8.3.1.2. Prochlorperazine
    • 8.3.2. NK1 Receptor Antagonists
      • 8.3.2.1. Aprepitant
      • 8.3.2.2. Fosaprepitant
    • 8.3.3. Serotonin Receptor Antagonists
      • 8.3.3.1. Granisetron
      • 8.3.3.2. Ondansetron
      • 8.3.3.3. Palonosetron
  • 8.4. H2 Receptor Antagonists
    • 8.4.1. Cimetidine
    • 8.4.2. Famotidine
    • 8.4.3. Nizatidine
    • 8.4.4. Ranitidine
  • 8.5. Laxatives
    • 8.5.1. Bulk Forming
      • 8.5.1.1. Methylcellulose
      • 8.5.1.2. Polycarbophil
      • 8.5.1.3. Psyllium
    • 8.5.2. Lubricant
    • 8.5.3. Osmotic
      • 8.5.3.1. Lactulose
      • 8.5.3.2. Polyethylene Glycol
      • 8.5.3.3. Sorbitol
    • 8.5.4. Stimulant
    • 8.5.5. Stool Softeners
  • 8.6. Probiotics & Prebiotics
    • 8.6.1. Prebiotics
      • 8.6.1.1. Fructooligosaccharides
      • 8.6.1.2. Inulin
    • 8.6.2. Probiotics
      • 8.6.2.1. Bifidobacterium
      • 8.6.2.2. Lactobacillus
      • 8.6.2.3. Saccharomyces Boulardii
  • 8.7. Proton Pump Inhibitors
    • 8.7.1. Esomeprazole
    • 8.7.2. Lansoprazole
    • 8.7.3. Omeprazole
    • 8.7.4. Pantoprazole
    • 8.7.5. Rabeprazole

9. Gastrointestinal Agents Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
    • 9.2.1. Bolus Injection
    • 9.2.2. Infusion
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Liquid Syrup
    • 9.3.3. Powder
    • 9.3.4. Tablet
  • 9.4. Topical
    • 9.4.1. Creams
    • 9.4.2. Gels
    • 9.4.3. Suppositories

10. Gastrointestinal Agents Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Gastrointestinal Agents Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gastrointestinal Agents Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gastrointestinal Agents Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AbbVie Inc.
    • 14.3.2. Takeda Pharmaceutical Company Limited
    • 14.3.3. Pfizer Inc.
    • 14.3.4. AstraZeneca PLC
    • 14.3.5. Johnson & Johnson
    • 14.3.6. Otsuka Pharmaceutical Co., Ltd.
    • 14.3.7. Novartis AG
    • 14.3.8. GlaxoSmithKline plc
    • 14.3.9. Sanofi S.A.
    • 14.3.10. Bayer AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GASTROINTESTINAL AGENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. GASTROINTESTINAL AGENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ALUMINUM HYDROXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CALCIUM CARBONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY MAGNESIUM HYDROXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SODIUM BICARBONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI DIARRHEALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ADSORBENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY KAOLIN PECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OPIOID DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DIPHENOXYLATE ATROPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LOPERAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ANTI EMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROCHLORPERAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY APREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FOSAPREPITANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PALONOSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY BULK FORMING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY METHYLCELLULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYCARBOPHIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PSYLLIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LUBRICANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY OSMOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY LACTULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY POLYETHYLENE GLYCOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY SORBITOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STIMULANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY STOOL SOFTENERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY FRUCTOOLIGOSACCHARIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY INULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY PROBIOTICS, 2018-2024 (USD MILLION)

TABL